Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01878435
Other study ID # OPP1053900
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2013
Est. completion date February 2016

Study information

Verified date October 2022
Source Johns Hopkins Bloomberg School of Public Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The project goal is to conduct a randomized controlled trial (RCT) to test whether mobile phone short message system (SMS) reminders, either with or without mobile-phone based travel subsidies will improve timeliness, coverage, and drop-out rates of routine EPI vaccines in rural western Kenya.


Recruitment information / eligibility

Status Completed
Enrollment 2018
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 0 Weeks to 5 Weeks
Eligibility Inclusion Criteria: 1. Mother of infant aged 0-4 weeks during the study period 2. Current resident of one of the study villages 3. Willing to sign informed consent for the study Exclusion Criteria: 1. Plans to move out of the study area in the next 6 months 2. Resides in a village with active immunization intervention/program 3. Has already received immunizations other than birth dose of BCG or polio

Study Design


Intervention

Other:
SMS reminder

Travel subsidy

Travel subsidy 2


Locations

Country Name City State
Kenya Gem and Asembo Area Gem And Asembo Area Siaya County

Sponsors (4)

Lead Sponsor Collaborator
Johns Hopkins Bloomberg School of Public Health Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention, Kenya Medical Research Institute

Country where clinical trial is conducted

Kenya, 

References & Publications (2)

Gibson DG, Kagucia EW, Ochieng B, Hariharan N, Obor D, Moulton LH, Winch PJ, Levine OS, Odhiambo F, O'Brien KL, Feikin DR. The Mobile Solutions for Immunization (M-SIMU) Trial: A Protocol for a Cluster Randomized Controlled Trial That Assesses the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya. JMIR Res Protoc. 2016 May 17;5(2):e72. doi: 10.2196/resprot.5030. — View Citation

Wakadha H, Chandir S, Were EV, Rubin A, Obor D, Levine OS, Gibson DG, Odhiambo F, Laserson KF, Feikin DR. The feasibility of using mobile-phone based SMS reminders and conditional cash transfers to improve timely immunization in rural Kenya. Vaccine. 2013 Jan 30;31(6):987-93. doi: 10.1016/j.vaccine.2012.11.093. Epub 2012 Dec 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of children immunized Up to 12 months of age
Secondary Percent of fully immunized children (FIC) by study arm FIC = One dose bacille Calmette-Guerin (BCG) vaccine, three doses pentavalent (diphtheria, pertussis, tetanus, hepatitis B, haemophilus influenzae type b) vaccine, three doses polio vaccine and one dose measles vaccine. The proportion of FIC infants by 10 months of age in each of the intervention arms (SMS only and SMS + subsidy) will be separately compared to the control arm using statistical analyses that adjust for the cluster design and any socio-demographic variables that may be unequally distributed across study arms 10 months of age
Secondary Proportion of children vaccinated by study arm The proportion of intervention arm infants that receive vaccination within 2 weeks of the scheduled date will be calculated for each dose of vaccine and compared to the control arm using statistical analyses that adjust for our cluster design and any socio-demographic variables that may be unequally distributed across study arms Within 2 weeks of each scheduled vaccine date
Secondary Proportion of children dropping out between doses Comparison of the differences in percentages of children vaccinated with pentavalent1 and pentavalent3 in the interventions arms compared to this difference in the control arm using statistical analyses that adjust for our cluster design and any socio-demographic variables that may be unequally distributed across study arms Age 24 weeks
Secondary Proportion of children receiving measles and pentavalent vaccines by study arm Comparison of vaccine coverage (pentavalent3 and measles, separately) between intervention and control arms Age 24 weeks (pentavalent only), 10 months and age 12 months
Secondary Proportion in each arm vaccinated by mobile phone ownership and by residential distance from a health facility Vaccine coverage analysis stratified by mobile phone ownership and residential distance Age 12 months
Secondary Height-for-age,to evaluate if the interventions had impact on other health status indicators Using regression, average height for age in each group will be compared across study groups Age 12 months
Secondary Direct costs for each intervention arm Costs include SMS messages, the amount of travel subsidy transferred, and the tariffs and fees that are associated with using mobile-money. For each arm, these costs will be divided by the number of children vaccinated and comparisons will be made across study arms 25 months, approximate time period for deploying interventions
Secondary Bed-net usage, to evaluate if the interventions had impact on other indicators of health status Proportion of children using bed-nets will be compared across study groups Age 12 months
Secondary Vitamin A coverage, o evaluate if the interventions had impact on other indicators of health status Proportion of children who have received vitamin A supplementation will be compared across study groups Age 12 months
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A